These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 9531434

  • 41. Long-term experience with continuous duodenal levodopa-carbidopa infusion (Duodopa): report of six patients.
    Raudino F, Garavaglia P, Pianezzola C, Riboldazzi G, Leva S, Guidotti M, Bono G.
    Neurol Sci; 2009 Feb; 30(1):85-6. PubMed ID: 19169622
    [No Abstract] [Full Text] [Related]

  • 42. [Levodopa intestinal infusion therapy in Parkinson's disease].
    Sławek J, Bogucki A.
    Neurol Neurochir Pol; 2010 Feb; 44(4):396-403. PubMed ID: 20827613
    [Abstract] [Full Text] [Related]

  • 43. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life.
    Puente V, De Fabregues O, Oliveras C, Ribera G, Pont-Sunyer C, Vivanco R, Cucurella G, Giralt E, Delgado T, Garcia C, Seoane A, Campo R.
    Parkinsonism Relat Disord; 2010 Mar; 16(3):218-21. PubMed ID: 19762271
    [Abstract] [Full Text] [Related]

  • 44. Clinical experience with duodenal infusions of levodopa for the treatment of motor fluctuations in Parkinson's disease.
    Sage JI, Sonsalla PK, McHale DM, Heikkila RE, Duvoisin RC.
    Adv Neurol; 1990 Mar; 53():383-6. PubMed ID: 2122646
    [No Abstract] [Full Text] [Related]

  • 45. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
    Block G, Liss C, Reines S, Irr J, Nibbelink D.
    Eur Neurol; 1997 Mar; 37(1):23-7. PubMed ID: 9018028
    [Abstract] [Full Text] [Related]

  • 46. Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism.
    Sage JI, Trooskin S, Sonsalla PK, Heikkila R, Duvoisin RC.
    Ann Neurol; 1988 Jul; 24(1):87-9. PubMed ID: 3415201
    [Abstract] [Full Text] [Related]

  • 47. [Practical Use of the Levodopa Pump].
    Südmeyer M, Ebersbach G, Holtmann M, Jost W, Odin P, Schrader C, Winkler C.
    Fortschr Neurol Psychiatr; 2016 Jul; 84(7):404-10. PubMed ID: 27471998
    [Abstract] [Full Text] [Related]

  • 48. Continuous duodenal infusions of levodopa.
    Fowler SB, Bergen M.
    J Neurosci Nurs; 1993 Oct; 25(5):317-20. PubMed ID: 8270813
    [Abstract] [Full Text] [Related]

  • 49. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
    Antonini A, Fung VS, Boyd JT, Slevin JT, Hall C, Chatamra K, Eaton S, Benesh JA.
    Mov Disord; 2016 Apr; 31(4):530-7. PubMed ID: 26817533
    [Abstract] [Full Text] [Related]

  • 50. Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease.
    Meppelink AM, Nyman R, van Laar T, Drent M, Prins T, Leenders KL.
    Mov Disord; 2011 Feb 01; 26(2):331-4. PubMed ID: 20960486
    [Abstract] [Full Text] [Related]

  • 51. A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion.
    Westin J, Nyholm D, Pålhagen S, Willows T, Groth T, Dougherty M, Karlsson MO.
    Clin Neuropharmacol; 2011 Feb 01; 34(2):61-5. PubMed ID: 21297456
    [Abstract] [Full Text] [Related]

  • 52. Continuous duodenal levodopa infusion in a patient with Crohn's disease and small bowel surgery - Case report.
    Tomic S, Skelac D, Mick D, Segec I, Resan B, Soldo SB.
    J Neurol Sci; 2015 Nov 15; 358(1-2):525-6. PubMed ID: 26443281
    [No Abstract] [Full Text] [Related]

  • 53. Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease.
    Zibetti M, Rizzone M, Merola A, Angrisano S, Rizzi L, Montanaro E, Cicolin A, Lopiano L.
    Acta Neurol Scand; 2013 May 15; 127(5):e28-32. PubMed ID: 23311399
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
    Hauser RA, Ellenbogen AL, Metman LV, Hsu A, O'Connell MJ, Modi NB, Yao HM, Kell SH, Gupta SK.
    Mov Disord; 2011 Oct 15; 26(12):2246-52. PubMed ID: 21755537
    [Abstract] [Full Text] [Related]

  • 57. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.
    Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L, Dal Fante M, Lopiano L, Pezzoli G.
    Mov Disord; 2007 Jun 15; 22(8):1145-9. PubMed ID: 17661426
    [Abstract] [Full Text] [Related]

  • 58. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
    Wirdefeldt K, Odin P, Nyholm D.
    CNS Drugs; 2016 May 15; 30(5):381-404. PubMed ID: 27138916
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A, Devos D, Seguy D, Dujardin K, Destée A, Defebvre L.
    Rev Neurol (Paris); 2009 May 15; 165(8-9):718-27. PubMed ID: 19150100
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.